Mizuho Securities Downgrades Valeant Pharmaceuticals (VRX) to Underperform

November 23, 2016 8:45 AM EST
Get Alerts VRX Hot Sheet
Price: $13.69 -2.14%

Rating Summary:
    10 Buy, 12 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 18 | New: 11
Trade VRX Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Mizuho Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Underperform with a price target of $11.00 (from $25.00).

Analyst Irina Koffler said, "We believe the risk/reward is unfavorable due to growth challenges, 2017 guidance risk, legal overhangs, and weaker asset divestitures. While we see no impending sell catalyst, we believe this stock will edge lower over the next 6-12 months as investor patience wanes. We downgrade to Underperform from Neutral, and lower our PT to $11 from $25."

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $17.83 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades, Hot Downgrades

Related Entities

Irina Koffler

Add Your Comment